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Abstract
A novel computational method for prediction of proteins excreted into urine is presented. The method is based on the
identification of a list of distinguishing features between proteins found in the urine of healthy people and proteins deemed
not to be urine excretory. These features are used to train a classifier to distinguish the two classes of proteins. When used in
conjunction with information of which proteins are differentially expressed in diseased tissues of a specific type versus
control tissues, this method can be used to predict potential urine markers for the disease. Here we report the detailed
algorithm of this method and an application to identification of urine markers for gastric cancer. The performance of the
trained classifier on 163 proteins was experimentally validated using antibody arrays, achieving .80% true positive rate. By
applying the classifier on differentially expressed genes in gastric cancer vs normal gastric tissues, it was found that
endothelial lipase (EL) was substantially suppressed in the urine samples of 21 gastric cancer patients versus 21 healthy
individuals. Overall, we have demonstrated that our predictor for urine excretory proteins is highly effective and could
potentially serve as a powerful tool in searches for disease biomarkers in urine in general.
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Introduction
The rapid advancement of omic techniques in recent years has
made it possible to search for biomarkers for specific human
diseases in a systematic and comprehensive manner, which is
substantially improving our ability to detect diseases at early
stages. Most of the previous biomarker studies have been focused
on serum markers [1], mainly because of the known richness of
serum in containing signals for various physiological and
pathophysiological conditions.
Compared to serum markers, existing urinary markers are
mostly related to urinary-tract or closely associated diseases. Only
within the last few years has improved proteomic analyses of urine
samples revealed that, like sera, urine is also a rich source of
information for detecting human diseases such as the graft-versus-
host disease and coronary artery disease [2,3,4]. Note that urine is
formed by filtration of blood through the kidneys; hence some
proteins in blood may pass through the filters and be excreted into
urine. As a result, the urinary proteins not only reflect the
conditions of the kidney and the urogenital tract, but also those of
other organs that may be distal from the kidney, as at least 30% of
the urinary proteins are not originally from the urogenital tract
[5,6]. The plethora of information in urine makes it an attractive
source for biomarker screening since, compared to serum, the
composition of urine is relatively simple, and urine collection is
easier and noninvasive [7,8].
Marker identification in urine could potentially be done through
comparative proteomic analyses of urine samples of patients with a
specific disease and control groups. The challenge in such searches
for urinary markers in a blind fashion is twofold. (a) Urine could
have a large number of proteins/peptides (in contrast to the
previous understanding [8]) with relatively low abundance. (b) The
dynamic range in the abundance of these proteins could span a
few orders of magnitude, wider than the range typically covered by
a mass spectrometer [9]. For these reasons, comparative analyses,
particularly (semi)quantitative analyses, of proteomic data of urine
samples can be very challenging. This might be a key reason that
there are no reliable urine markers for cancer diagnosis.
Our study focuses on development of a computational method
for accurately predicting proteins that are urine excretory (see
Figure 1 for the outline of the approach). These proteins must have
specific properties that allow them to be secreted from cells first and
thentobefilteredoutthroughtheglomerulusmembraneinkidneys.
A recent proteomic study identified more than 1,500 proteins/
peptides that are excreted into urine through healthy glomerular
membranes [8]. Using this set of proteins and proteins deemed not
to be urine excretory, we have identified a list of distinguishing
features between these two classes of proteins and trained a support
vector machine (SVM) based classifier to predict if a given protein
might be excreted into urine. The prediction method was
experimentally validated using antibody arrays in conjunction with
Western blots, and the results are highly encouraging.
PLoS ONE | www.plosone.org 1 February 2011 | Volume 6 | Issue 2 | e16875This classifier has been applied to predict proteins that might be
excreted into urine based on the identified differentially expressed
genes in gastric cancer versus reference gastric tissues; and a
number of potential urine markers for gastric cancer have been
identified. A key contribution made in this work is that it provides
a new and effective way to guide proteomic studies of urine by
suggesting candidate marker proteins, hence allowing targeted
marker searches using antibody-mediated techniques like Western
blots and Elisa, which are substantially more feasible than large-
scale comparative proteomic analyses of urine samples without any
targets with which to work. While this prediction program has
been applied to gastric cancer data in this study, no gastric cancer-
specific information was used in this program; hence, it can be
used for urine marker searches for other diseases.
Methods
This study consists of three main components: (i) construction of
a classifier for predicting urine excretory proteins; (ii) evaluation of
the performance of the classifier by applying it to a set of proteins
for which the excretory status of the proteins is known; and (iii)
application of the validated classifier to gene-expression data of
gastric cancer to demonstrate its effectiveness in solving the urine
marker identification problem.
This research was approved by the Institutional Review Board
at the University of Georgia, Athens, Georgia, USA (Office of the
Vice President for Research DHHS Assurance ID NO.
FWA00003901, Project Number 2009-10705-1)and by the
Chinese Institutional Review Board overseeing human subjects
at Jilin University College of Medicine, Changchun, China. A
consent form, approved by IRB at the University of Georgia and
Chinese IRB, was collected from each subject. All subjects are
aware that any data from research may be used for documents or
publications as stated in the consent form.
a. An algorithm for predicting excretory proteins
The general understanding of protein excretion from tissues to
urine is that some proteins are secreted or leaked from cells into
blood circulation, and then a portion of these proteins, along with
some native proteins in blood, may be excreted into urine. Our
goals are first to identify distinguishing features for such urine
excretory proteins and then to build a classifier based on these
features to predict which proteins in cells can be excreted into
urine. To the best of our knowledge, there has not been any
published work aimed to solve this problem. The importance in
having such a capability is that it provides an effective link in
connecting omic analyses of tissues to marker search in urine by
providing candidate markers in urine that can be studied using
antibody-based approaches.
The first step in developing such a predictive capability, i.e., a
classifier, is to have a training dataset containing proteins that can and
that cannot be excreted into urine, based on which a set of
distinguishing features could possibly be identified. Fortunately, we
havefound onelarge proteomic dataset of urine samples fromhealthy
people in a recently published study [8], which contains more than
1,500 unique proteins of which 1,313 have SwissProt accession IDs.
Wehave used these 1,313 proteins as the positive training data for the
to-be-trained classifier. The following procedure was then used to
generate a negative training set: arbitrarily select at least one protein
from each Pfam family that does not contain any positive training
data, and the number of selected proteins from each family is
Figure 1. The flow of the study.
doi:10.1371/journal.pone.0016875.g001
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proteins were selected and used as the negative training set.
We examined 18 physiochemical features computed from
protein sequences, which are potentially useful for the classification
problem based on the general understanding of urinary excretion
of proteins. The details of the 18 features and the computer
programs used to calculate them are listed in Table S1. Some of
these features are represented by multiple feature values, e.g., the
amino acid composition in a protein sequence is represented by 20
feature values; overall the 18 features are represented using 243
feature values. We then identified a subset of features values from
the 243, which can distinguish between the positive and the
negative training data using an SVM-based classifier. The RBF
kernel was used in our SVM training, considering its capability to
handle non-linear attributes [12,13].
To ascertain which of the initially considered features are actually
useful, the feature selection tool provided in LIBSVM [12] was used
to select the most discerning features among the 243. Other feature
selection tools could possibly be used but we have considerable
experienceinusingthistooland foundittobeadequate.Codesused
in this are publicly available from LIBSVM website (http://www.
csie.ntu.edu.tw/,cjlin/libsvm/); we also have made the relevant
program accessible at http://seulgi.myweb.uga.edu/files. An F-
score [12], defined as follows, is used to measure the discerning
power of each feature value to our classification problem,
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where Xk refers to the training feature values (k=1,…, m); n+ and
n2 are the number of proteins in the positive (+) and negative (-)
training dataset, respectively; xi, xz
i , x{
i are the averages of the
ith feature value across the whole training dataset, the positive
dataset and the negative dataset, respectively; and xz
k,i and x{
k,i are
the ith feature of the kth protein in the positive and negative
training data, respectively. Generally, the larger an F-score, the
more discriminative the corresponding feature is. In our selection,
all features with F-scores above a pre-selected threshold were
retained and used in training the final classifier. To find an optimal
F-score threshold, we considered a list of possible thresholds and
then selected the best one based on the training results.
The training of our SVM-based classifier is done using a
standard procedure provided in LIBSVM [12] to find values of
two parameters C and c that give an optimal classification on the
training data, where C controls the trade-off between training
errors and classification margins, and c determines the width of
the kernel used [12]. Our training procedure is summarized as
follows[12]:
a. Obtain the F-score for each feature value;
b. For each of the pre-selected thresholds, do the following
i. Remove the feature values with F-scores lower than the
threshold;
ii. Randomly split the training data into a sub-training and a
sub-validation sets with equal size;
iii. Train an SVM with an RBF kernel on the sub-training set
to search for optimal values of C and c, and then apply it to
the sub-validation data and calculate the classification
error;
iv. Repeat steps (i) – (iii) five times and calculate the average
validation error;
c. Choose the threshold that gives the lowest average validation
error, and keep the features with F-score above the selected
threshold; and
d. Retrain an SVM based on the selected features as the final
classifier.
b. Datasets used to evaluate the performance of the
classifier
An independent dataset was used to assess the performance of
the trained classifier for which the excretory status of each protein
is known. The positive subset of this dataset has 460 human
proteins found in the urine of healthy individuals by three urinary
proteomics studies [14,15,16], and the negative subset contains
2,148 proteins selected using the same procedure described
previously but does not overlap with the negative set used for
training.
The following measures were used to assess the classification
accuracies: the sensitivity, the specificity, the accuracy, the
Matthew’s correlation coefficient, and the AUC [17]. Table 1
summarizes the classification accuracies of the trained classifier on
the both training and the test datasets [17]. From the classification
accuracies on the two datasets, we believe that our trained
classifier captured the key distinct features of the excretory
proteins in urine.
In addition, our classifier was tested on a separate dataset, a
subset of the 274 proteins fixed on a pre-made protein antibody
array (the RayBio Human G-series Array 4000 (RayBiotech, Inc.,
Norcross, GA)). Of the 274 proteins, 111 are known to be
excretory and were included in our training or independent test
dataset. We applied the classifier on the remaining 163 proteins for
which the excretory status was unknown (see Results and Table
S2). This protein array provides the relative expression level for
each protein on the array when tested on a (urine) sample, which is
measured in terms of the signal intensity, quantified by the
densitometry. The background of the array was used as the control
to determine the actual presence of a protein in the (urine) sample.
The signal intensity for a protein was considered as a true signal if
it was at least 5-fold higher than that of the control, as suggested by
the manufacturer’s recommendation. We focused our experimen-
tal validation on confirming the positive predictions only since it is
virtually impossible to prove a protein is not present in a urine
sample due to limitations in detection sensitivity of the current
technology when the protein is of very low concentration in the
sample.
c. Urine sample collection/preparation
Urine samples from gastric cancer patients and healthy controls
were collected at the Medical School of Jilin University,
Changchun, China. Gastric cancer patients, from who the samples
were collected from, are all late stage patients (see Table S3 for
patient information). These samples were immediately lyophilized
and stored at 280uC until further use after their surgical removal
from the patients. They were then reconstituted and centrifuged
(3,000xg for 25 min at 4uC) to remove cellular components. The
supernatants were collected and dialyzed at 4uC against Millipore
ultra pure water (three buffer changes followed by an overnight
dialysis) using Slide-A-Lyzer Dialysis Cassettes (Thermo Fisher
Scientific, Rockford, IL). Protein concentrations were measured
using the Bio-Rad Protein Assay (Bio-Rad, Hercules, CA) with
bovine serum albumin as a standard.
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in gastric cancer and control tissues
A total of 80 gastric cancer tissues and their adjacent
noncancerous tissues from 80 patients were collected at the
Medical School of Jilin University. Microarray experiments were
conducted on these tissues using the Affymetrix GeneChip Human
Exon 1.0 ST Array, which covers 17,800 human genes. The
PLIER algorithm [18] was used to summarize the probe signals to
gene-level expressions. For each gene, we examined the distribu-
tion of the expression fold-change between the paired cancer and
control tissues across all 80 pairs of tissues. Let Kexp, be the number
of pairs of tissues whose fold-change is at least 2. A gene is
considered as differentially expressed if the p-value of the observed Kexp
is less than 0.05. Using this criterion, a total of 715 genes were
found to be differentially expressed in gastric cancer across all
human genes, and the names of the 715 genes, along with the
associated Kexp and p-values, are given in Table S4. A detailed
study of the microarray data has been reported elsewhere [19].
e. Function and pathway enrichment analyses
The DAVID Bioinformatics Resources and the KOBAS web
server [20,21] were used to do functional and pathway enrichment
analysis, respectively, for all the predicted urine-excretory proteins,
using the whole set of human proteins as the background. We refer
the readers to [20,21] for details on the methods for functional and
pathway enrichment analyses. Using DAVID Bioinformatics
Resources, the enrichment score for a specified group of proteins
was determined by the EASE score [20,22]. KOBAS is a
complementary tool to DAVID as it expands the gene annotation
using KEGG Orthology (KO) terms. The KOBAS web server,
along with the KO-based annotation system [21,23], was used to
find statistically enriched and underrepresented pathways among
the predicted urine-excreted proteins. KOBAS takes in a set of
protein sequences and annotates them using the KO terms. The
annotated KO terms were then compared against all human
proteins as the background set for assessing if they are enriched or
underrepresented.
f. Western blots
Urinary proteins from each sample (total of 2 mg) were
combined with 3x sample dye. Each tube was boiled for 5 min
and loaded on SDS-PAGE gels, along with 10 ml standards and
run for 1 h at 200 volts. The membrane was activated with 100%
methanol, following a transfer from the gel to the membrane (100
volts for 1 h). Once the transfer was complete, the membrane was
allowed to dry, rewetted in 100% methanol and washed 2X for
5 min each with Tris-Buffered Saline (TBS). The membrane was
then incubated in 3% milk blocking solution for 2 h at room
temperature. Next the membrane was incubated in the first
antibody solution (1:200 dilutions in 1.5% milk blocking) for 1 h at
room temperature, and the unbound antibody was removed by
washing the membrane 3X with TBS Tween-20 (TBST) solution
for 10 min each. Then the membrane was incubated in a 1:10,000
dilution of the secondary antibody in 1.5% milk blocking solution
for 1 h at room temperature. The membrane was washed 3X with
TBST and 2X with TBS (10 min each). Lastly, the membrane was
covered completely with an equal amount of enhancer and
peroxide solution from a Pierce Western Blotting kit for 5 min and
exposed to the film. Each experiment was repeated multiple times
to ensure reproducibility [24]. The signal intensities were
determined using the imageJ software [25]. For each membrane,
the blank lane was used to normalize the signal intensities across
the membranes. The performance was examined using ROC and
whisker-box plot.
Results and Discussion
a. Signal peptide and secondary structures are key
features of urine-excreted proteins
The initial list of features was carefully selected to include what
we believed to be protein characteristics relevant to urinary
excretion based on literature search and our current understand-
ing of urinary proteins. For example, the negatively charged
glomerular wall in kidney will allow the filtration of only positively
or neutrally charged proteins. Thus, charge of a protein is one of
the features we selected. Taking the available information into
consideration, the total number of feature values collected initially
was 243, representing basic sequence properties, motifs, physico-
chemical properties, and structural properties (Table S1). In
identifying features that are effective in discriminating urine
excretory proteins from the non-excretory ones, a simple and
effective method to eliminate features that show little or no
discerning power for our classification problem was employed; 74
feature values were selected using the procedure outlined in
Section a of Methods (Table S5). These feature values were used to
train the final classifier.
Among the selected features, the most discriminatory one was
the presence of signal peptides. It is understood that proteins that
are secreted through the ER have signal peptides and are
trafficked to their destination according to the specific signal
peptides; thus, not surprisingly, most excreted proteins have this
feature. Another prominent feature was the secondary structure
type; specifically, the percentage of alpha helices in a protein
sequence was ranked as the number 2 feature value among the
selected 74 (Table S5). As expected, the charge of a protein was
among the top ranked features for excreted proteins. This is
consistent with the general understanding that charge is a factor in
determining which proteins can be filtered through the glomerular
membrane [26] as proteins inside glomerular membranes and
podocyte slits are negatively charged, and hence negatively
charged proteins will have low chances to filter through the
kidneys. Indeed, the feature values of positive amino acids and
charge were among the top ranked feature values.
Interestingly, however, molecular weight, which ranked at 232
out of 243, was not included in the final 74 feature values. This
Table 1. Classification performance by the trained classifier on the training and an independent test set.
Sets TP TN FP FN SEN SP ACC MCC AUC
Train 972 2,493 134 341 0.74 0.95 0.88 0.52 0.94
Independent 360 1,983 165 100 0.78 0.92 0.90 0.45 0.93
TP=true positive; TN=true negative; FP=false positive; FN=false negative; N= total number of proteins in dataset; SEN = TP/(TP+FN); SP = TN/(TN+FP); ACC =
(TP+TN)/N; MCC =(TPxTN-FPxFN)/!((TP+FN)(TP+FP)(TN+FP) (TN+FN)); AUC is described in (37).
doi:10.1371/journal.pone.0016875.t001
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may have already undergone a cleavage or have been partially
degraded, and thus may not be in their intact or complete form
when they enter the kidney. It has, in fact, been established that
the majority of proteins found in urine are extensively degraded
[27]. While an intact protein may not be able to filter through the
glomerulus due to its size or shape, a protein-derived peptide may
easily pass through the podocyte slits. As a result, the molecular
weight of the intact protein is a non-factor in predicting if the
protein is urine excretory.
It should be noted that urine excretory proteins and secreted
proteins share some common characteristics as some of the
features used to identify blood-secreted proteins in our previous
study [10] were selected in the urinary protein prediction in this
study. For example, features such as solvent accessibility, polarity,
and signal peptides were included in both classifiers. However
there is a clear difference between the features used in the two
classifiers. While features such as beta-strand-content, features
associated with beta-barrel transmembrane protein and protein
ratio, TatP motif, transmembrane domain, protein size, and the
longest disordered region were among the top features for
prediction of blood-secretory proteins [10], they were not included
in the final features for the urinary protein prediction. Moreover,
features related to positive charge, such as the composition of
positively charged amino acids, were prominent in urinary protein
prediction but not selected in the blood secretion prediction.
Similarly, the alpha-helix-content and the coil-content of proteins
were among the top features for urinary protein prediction, but
they were not selected for the blood-secretory protein prediction.
It is interesting to note that in contrast to the finding that beta-
strands are a common secondary structure type among the blood
secretory proteins, urinary proteins tend to have higher alpha-
helix and coil content, which indicates that the urinary proteins
possess properties not shared by blood secretory proteins in
general.
b. Performance of the classifier
To determine the accuracy of the final classifier, we tested it on
an independent test set, which consists of 460 experimentally
validated urine excretory proteins and 2,148 non-urine excretory
proteins. Our classifier has its prediction sensitivity and specificity
on this independent test set at 0.78 and 0.92, respectively (Table 1).
We then ran the classifier on the 163 out of the 274 proteins
fixed on the pre-made antibody array (see Methods), for which the
excretory status was unknown. Of the 163 proteins, 112 proteins
were predicted to be urine excretory by our classifier. To assess the
performance of this prediction, antibody array-based experiments
were conducted on 14 urine samples, seven from healthy
individuals and seven from gastric cancer patients. Of the 112
predicted urine-excretory proteins, 92 were found in at least one of
the urine samples (Table S6), giving a positive prediction rate of
0.81, which is consistent with the performance level on the first test
set.
It should be noted that one limitation of this classifier is that
some proteins might have been partially degraded before being
excreted into urine or in urine, making it difficult for our
classifier to detect so formed peptides as it was trained on
whole intact proteins. This issue will be addressed in the future
through deriving feature values based on the actual proteins/
peptides identified in previous urinary proteomic studies rather
than their corresponding full-length proteins as done in this
study. While there is clearly room for further improvement,
the prediction results of the current classifier are highly
encouraging.
c. Application of classifier to gastric cancer data
Our previous study on 160 sets of microarray gene-expression
data of gastric cancer has identified 715 differentially expressed
genes with at least 2-fold changes in gastric cancer versus control
tissue samples [19]. While it would be preferable to have
proteomic data of the tissue samples, we have only gene-expression
data available in this study. Hence, gene expression data are being
used as an approximation to the protein expression in this
methodology-oriented study. Our classifier was applied to these
715 proteins, and it predicted that 201 of the 715 proteins are
urine excretory. Table S7 provides the detailed information of the
201 proteins. Since it is unrealistic to check all the 201 proteins in
this study to determine if they are urine excretory or not, we did
analyses to narrow down this list. Specifically, we have carried out
the following analyses: (i) functional and pathway enrichment
analyses to gain a better understanding of the types of proteins
present in urine, (ii) literature search on urinary proteins to
compile information about published urinary marker proteins, (iii)
examining the gene expression data to remove genes that are not
substantially differentially expressed between cancer and control
tissue samples; and (iv) Western blots on proteins chosen from a
narrowed down list of the 201 proteins. This procedure showed a
high success rate and led to an interesting discovery of potential
biomarker for gastric cancer.
For (i), we have carried out functional and pathway enrichment
analyses on all the 201 proteins using the DAVID [20] and
KOBAS [21] servers, respectively. We found that the enriched
functional groups included the extracellular matrix (ECM), cell
adhesion, and development, cell motility, defense response,
angiogenesis, which are all known to be involved in the
development of or in defense of cancer (Figure S1A). The most
enriched pathways were ECM-receptor interaction and inorganic
ion transport and metabolism pathways (Figure S1B).
The following criterion was used to reduce the list of 201
proteins for steps (ii) - (iii): the proteins have not been reported to be related
to any cancer based on our extensive literature search, which gives rise to 71
proteins. The list was further reduced based on a pre-selected
cutoff on differential expressions and functional annotations
(potentially relevant to gastric cancer rather than immune
responses).
d. Endothelial lipase is substantially reduced in the urine
samples of gastric cancer patients
We chose six proteins (MUC13, COL10A1, AZGP1, LIPF,
MMP3, and EL) for experimental validation from the above
narrowed down list. To do this, we have collected urine samples of
21 gastric cancer patients and 21 healthy individuals. Of the six
selected proteins, five proteins, MUC13, COL10A1, LIPG,
AZGP1, and EL were detected by Western blots in at least one
urine sample. Out of the five, MUC13, COL10A1, and EL were
detected even at a very low quantity of the total urinary proteins
(1–2 mg). MMP3 was not found in the samples we tested, which
may be due to the low concentration of MMP3 in urine or a false
prediction by our classifier.
It is particularly interesting to note that we were able to detect
consistent differences in the EL abundance (encoded by LIPG)
between the two sets of 21 urine samples. The Western blots for
EL showed a substantial reduction in its abundance in urine
samples of the 21 gastric cancer patients compared to the control
samples. As shown in Figure 2A, the majority of the control
samples showed the presence of EL, whereas most of the gastric
cancer samples had relatively low amounts of EL. This pattern was
observed repeatedly.
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68 kDa [28]; thus, a homo-dimer is expected to be 134 kDa. In the
Western blots, however, bands were detected at near 100 kDa. This
probably corresponds to a partially cleaved homo-dimer, an active
form of which was confirmed by a previous study [29], although the
possibility of a monomeric form of EL associated with another
protein cannot be ruled out. The Western blots do provide semi-
quantitative information based on the signal intensities. The ROC
curve suggests that the EL concentration was discriminant in
distinguishing the gastric cancer samples from the non-gastric
cancer samples, yielding an AUC greater than 0.9 (Figure 2B–C).
Using 5,000 as a signal intensity cutoff, true positive rate and false
positive rate were 85% and 9.5%, respectively.
A further study is required to assess EL as a gastric cancer
biomarker. The limited sample size of 21 samples in each group is
too small to accurately evaluate its potential for biomarker.
Enrolling many more patients is needed to confirm the efficacy of
EL as a potential biomarker for clinical purposes. Also, it would be
interesting to test EL on the early stage of gastric cancer, as our
sampleswere all from late stage gastric cancer patients.Nonetheless,
our preliminary result shows highly encouraging results.
Concluding remarks
The available evidence indicates that many proteins are excreted
into urine that may be good biomarker candidates for different
diseases. The novel computational method developed and used
herein for predicting excreted proteins may aid in identifying these
and other biomarkers in urine. Our study has demonstrated that the
integrated approach, coupling bioinformatics prediction with
experimental validation, is an effective paradigm for identification
and validation of potential urinary biomarkers. We anticipate that
this approach will provide a powerful tool in the future for urinary
proteomics and biomarker studies in general.
Supporting Information
Figure S1 Functional and pathway analyses. A. Enriched
functional groups as identified by DAVID. The x-axis represents
the functional groups, and the y-axis represents the enrichment
score. B. Enriched pathways for 201 predicted urine proteins using
the KOBAS web server. Each blue bar represents the percentage
of the 201 proteins; each red bar indicates all human proteins; the
x-axis indicates the pathway names; and the y-axis indicates the
percentage.
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